Interestingly, both CXCL10 and CXCL11 have been reported to potently inhibit the lymphangiogenic process [51,52], making them very attractive candidates as possible mediators of SSc-related, disturbed lymphangiogenesis, and are worthy of future investigation. Here, CXCL11 is linked to systemic sclerosis.